CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • United States
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Alimera Sciences, Inc. - ALIM CFD

    2.41
    3.21%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.24
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.025457%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.003235%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.49
    Open* 2.51
    1-Year Change* -55.81%
    Day's Range* 2.38 - 2.51
    52 wk Range 1.30-7.92
    Average Volume (10 days) 107.41K
    Average Volume (3 months) 13.10M
    Market Cap 19.10M
    P/E Ratio -100.00K
    Shares Outstanding 7.40M
    Revenue 55.78M
    EPS -2.44
    Dividend (Yield %) N/A
    Beta 1.39
    Next Earnings Date Jul 25, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Jun 9, 2023 2.41 -0.03 -1.23% 2.44 2.52 2.35
    Jun 8, 2023 2.49 -0.15 -5.68% 2.64 2.65 2.41
    Jun 7, 2023 2.62 -0.05 -1.87% 2.67 2.71 2.57
    Jun 6, 2023 2.75 0.10 3.77% 2.65 2.89 2.64
    Jun 5, 2023 2.71 0.18 7.11% 2.53 2.80 2.53
    Jun 2, 2023 2.57 0.06 2.39% 2.51 2.66 2.50
    Jun 1, 2023 2.52 -0.08 -3.08% 2.60 2.60 2.51
    May 31, 2023 2.67 0.19 7.66% 2.48 2.67 2.48
    May 30, 2023 2.52 0.05 2.02% 2.47 2.55 2.47
    May 26, 2023 2.49 0.08 3.32% 2.41 2.52 2.35
    May 25, 2023 2.48 -0.02 -0.80% 2.50 2.51 2.37
    May 24, 2023 2.41 0.23 10.55% 2.18 2.42 2.14
    May 23, 2023 2.32 -0.19 -7.57% 2.51 2.55 2.21
    May 22, 2023 2.45 0.28 12.90% 2.17 2.72 2.15
    May 19, 2023 2.23 0.12 5.69% 2.11 2.30 2.02
    May 18, 2023 2.34 -0.26 -10.00% 2.60 3.05 2.26
    May 17, 2023 1.93 0.11 6.04% 1.82 1.94 1.78
    May 16, 2023 1.79 0.21 13.29% 1.58 1.92 1.58
    May 15, 2023 1.57 -0.03 -1.88% 1.60 1.68 1.56
    May 12, 2023 1.56 -0.05 -3.11% 1.61 1.64 1.55

    Alimera Sciences, Inc. Events

    Time (UTC) Country Event
    Wednesday, July 12, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Alimera Sciences Inc Annual Shareholders Meeting
    Alimera Sciences Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Tuesday, July 25, 2023

    Time (UTC)

    12:30

    Country

    US

    Event

    Q2 2023 Alimera Sciences Inc Earnings Release
    Q2 2023 Alimera Sciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, November 13, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Alimera Sciences Inc Earnings Release
    Q3 2023 Alimera Sciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 54.129 59.029 50.82 53.943 46.599
    Revenue 54.129 59.029 50.82 53.943 46.599
    Cost of Revenue, Total 7.977 7.03 6.941 6.626 4.308
    Gross Profit 46.152 51.999 43.879 47.317 42.291
    Total Operating Expense 65.769 57.438 51.321 59.217 58.035
    Selling/General/Admin. Expenses, Total 38.858 35.843 32.036 38.958 38.042
    Research & Development 16.228 13.778 9.668 10.992 11.274
    Depreciation / Amortization 2.706 2.579 2.676 2.641 2.645
    Unusual Expense (Income) 0 -1.792 0 1.766
    Operating Income -11.64 1.591 -0.501 -5.274 -11.436
    Interest Income (Expense), Net Non-Operating -5.789 -4.997 -4.906 -4.953 -4.84
    Net Income Before Taxes -18.079 -3.934 -5.407 -10.227 -16.276
    Net Income After Taxes -18.107 -4.372 -5.339 -10.443 -16.382
    Net Income Before Extra. Items -18.107 -4.372 -5.339 -10.443 -16.382
    Net Income -18.107 -4.372 -5.339 -10.443 -16.382
    Income Available to Common Excl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
    Income Available to Common Incl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
    Diluted Net Income -18.107 -4.372 -5.339 -10.443 21.948
    Diluted Weighted Average Shares 6.99685 6.59524 5.11766 4.7702 5.91587
    Diluted EPS Excluding Extraordinary Items -2.58788 -0.6629 -1.04325 -2.18921 3.71002
    Diluted Normalized EPS -2.58788 -0.83951 -1.04325 -2.18921 3.90406
    Other Operating Expenses, Total
    Total Extraordinary Items 0 0
    Total Adjustments to Net Income 0 38.33
    Other, Net -0.65 -0.528
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 13.546 14.029 13.598 14.604 11.898
    Revenue 13.546 14.029 13.598 14.604 11.898
    Cost of Revenue, Total 2.028 2.125 2.006 2.166 1.68
    Gross Profit 11.518 11.904 11.592 12.438 10.218
    Total Operating Expense 16.848 16.137 17.009 16.578 16.045
    Selling/General/Admin. Expenses, Total 9.975 9.099 9.856 9.81 10.093
    Research & Development 4.164 4.23 4.483 3.932 3.583
    Depreciation / Amortization 0.681 0.683 0.664 0.67 0.689
    Operating Income -3.302 -2.108 -3.411 -1.974 -4.147
    Interest Income (Expense), Net Non-Operating -1.68 -1.621 -1.567 -1.345 -1.256
    Net Income Before Taxes -4.968 -3.781 -5.245 -3.098 -5.955
    Net Income After Taxes -4.968 -3.78 -5.257 -3.115 -5.955
    Net Income Before Extra. Items -4.968 -3.78 -5.257 -3.115 -5.955
    Net Income -4.968 -3.78 -5.257 -3.115 -5.955
    Income Available to Common Excl. Extra. Items -4.982 -3.78 -5.257 -3.115 -5.955
    Income Available to Common Incl. Extra. Items -4.982 -3.78 -5.257 -3.115 -5.955
    Diluted Net Income -4.982 -3.78 -5.257 -3.115 -5.955
    Diluted Weighted Average Shares 7.03223 7.00032 6.99658 6.99971 6.99074
    Diluted EPS Excluding Extraordinary Items -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
    Unusual Expense (Income) 0 0 0
    Other, Net 0.014 -0.052 -0.267 0.221 -0.552
    Total Adjustments to Net Income -0.014
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 29.413 42.16 34.906 32.745 34.848
    Cash and Short Term Investments 5.274 16.51 11.208 9.426 13.043
    Cash & Equivalents 5.274 16.51 11.208 9.426 13.043
    Total Receivables, Net 19.612 19.128 17.2 19.331 17.259
    Accounts Receivable - Trade, Net 19.612 19.128 17.2 19.331 17.259
    Total Inventory 1.605 2.679 2.746 1.39 2.405
    Prepaid Expenses 2.892 3.809 3.718 2.565 2.109
    Other Current Assets, Total 0.03 0.034 0.034 0.033 0.032
    Total Assets 42.602 58.52 50.855 50.309 54.108
    Property/Plant/Equipment, Total - Net 3.92 4.493 2.358 2.047 1.355
    Property/Plant/Equipment, Total - Gross 7.981 7.923 6.305 5.858 4.967
    Accumulated Depreciation, Total -4.061 -3.43 -3.947 -3.881 -3.612
    Intangibles, Net 8.957 10.897 12.838 14.783 16.723
    Other Long Term Assets, Total 0.129 0.137 0.753 0.734 1.182
    Total Current Liabilities 39.732 12.592 12.348 12.048 10.234
    Accounts Payable 10.088 8.706 7.461 7.077 6.355
    Accrued Expenses 3.998 3.617 3.197 4.716 3.643
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 25.646 0.269 1.69 0.255 0.236
    Other Current Liabilities, Total
    Total Liabilities 63.41 61.125 58.833 54.754 51.386
    Total Long Term Debt 18.683 43.08 42.922 38.752 38.178
    Long Term Debt 18.683 43.08 42.408 38.658 37.873
    Capital Lease Obligations 0.514 0.094 0.305
    Other Liabilities, Total 4.995 5.453 3.563 3.954 2.974
    Total Equity -20.808 -2.605 -7.978 -4.445 2.722
    Preferred Stock - Non Redeemable, Net 19.227 19.227 19.227 30.344 30.344
    Common Stock 0.07 0.069 0.057 0.05 0.701
    Additional Paid-In Capital 378.238 377.229 365.83 350.117 346.108
    Retained Earnings (Accumulated Deficit) -415.388 -397.281 -392.539 -383.863 -373.42
    Other Equity, Total -2.955 -1.849 -0.553 -1.093 -1.011
    Total Liabilities & Shareholders’ Equity 42.602 58.52 50.855 50.309 54.108
    Total Common Shares Outstanding 6.99551 6.93515 5.71937 4.96595 4.67193
    Total Preferred Shares Outstanding 0.6 0.6 0.6 0.61015 0.61015
    Long Term Investments 0.183 0.833
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 35.675 29.413 29.76 33.073 34.753
    Cash and Short Term Investments 13.086 5.274 5.514 7.859 9.946
    Cash & Equivalents 13.086 5.274 5.514 7.859 9.946
    Total Receivables, Net 18.433 19.612 19.142 20.319 18.776
    Accounts Receivable - Trade, Net 18.433 19.612 19.142 20.319 18.776
    Total Inventory 1.215 1.605 1.786 1.656 2.452
    Prepaid Expenses 2.91 2.892 3.29 3.208 3.546
    Other Current Assets, Total 0.031 0.03 0.028 0.031 0.033
    Total Assets 48.239 42.602 43.429 47.574 49.931
    Property/Plant/Equipment, Total - Net 3.757 3.92 3.87 3.938 4.343
    Intangibles, Net 8.479 8.957 9.446 9.935 10.419
    Other Long Term Assets, Total 0.131 0.129 0.118 0.126 0.134
    Total Current Liabilities 14.173 39.732 34.01 25.431 17.006
    Accounts Payable 9.669 10.088 8.706 7.614 6.604
    Accrued Expenses 4.241 3.998 3.661 3.316 3.046
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.263 25.646 21.643 14.501 7.356
    Total Liabilities 67.155 63.41 61.507 59.909 58.534
    Total Long Term Debt 44.312 18.683 22.492 29.297 36.245
    Long Term Debt 44.152 18.683 22.492 29.297 36.245
    Capital Lease Obligations 0.16
    Other Liabilities, Total 8.67 4.995 5.005 5.181 5.283
    Total Equity -18.916 -20.808 -18.078 -12.335 -8.603
    Preferred Stock - Non Redeemable, Net 7.728 19.227 19.227 19.227 19.227
    Common Stock 0.074 0.07 0.07 0.07 0.07
    Additional Paid-In Capital 378.146 378.238 378.005 377.847 377.541
    Retained Earnings (Accumulated Deficit) -402.081 -415.388 -411.608 -406.351 -403.236
    Other Equity, Total -2.783 -2.955 -3.772 -3.128 -2.205
    Total Liabilities & Shareholders’ Equity 48.239 42.602 43.429 47.574 49.931
    Total Common Shares Outstanding 7.39159 6.99551 6.99802 6.99546 6.99265
    Total Preferred Shares Outstanding 0.012 0.6 0.6 0.6 0.6
    Long Term Investments 0.197 0.183 0.235 0.502 0.282
    Other Current Liabilities, Total
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -18.107 -4.372 -5.339 -10.443 -16.382
    Cash From Operating Activities -9.975 -3.224 -2.193 -4.152 -11.553
    Cash From Operating Activities 2.706 2.579 2.676 2.641 2.645
    Deferred Taxes 0.116 0.61 0.031 0.454 -0.653
    Non-Cash Items 2.621 -0.692 1.829 3.377 7.084
    Cash Taxes Paid 0.232 0.112 0.11 0.239 0.239
    Cash Interest Paid 4.489 4.302 4.556 4.419 3.571
    Changes in Working Capital 2.689 -1.349 -1.39 -0.181 -4.247
    Cash From Investing Activities -0.255 -0.621 -0.62 -0.174 -0.175
    Capital Expenditures -0.255 -0.621 -0.62 -0.174 -0.175
    Cash From Financing Activities -0.302 9.823 3.882 0.869 0.95
    Financing Cash Flow Items -0.113 0 -0.019 -2.227 -3.808
    Issuance (Retirement) of Stock, Net 0.1 10.044 0.049 0.902 0.085
    Issuance (Retirement) of Debt, Net -0.289 -0.221 3.852 2.194 4.673
    Foreign Exchange Effects -0.708 -0.676 0.714 -0.159 -0.248
    Net Change in Cash -11.24 5.302 1.783 -3.616 -11.026
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.968 -18.107 -14.327 -9.07 -5.955
    Cash From Operating Activities -2.209 -9.975 -9.724 -7.811 -6.213
    Cash From Operating Activities 0.681 2.706 2.023 1.359 0.689
    Non-Cash Items 0.507 2.621 2.095 1.318 1.027
    Cash Taxes Paid 0 0.232 0.224 0.182 0.018
    Cash Interest Paid 1.354 4.489 3.253 2.145 1.061
    Changes in Working Capital 1.571 2.689 0.485 -1.418 -1.974
    Cash From Investing Activities -0.009 -0.255 -0.171 -0.041 -0.149
    Capital Expenditures -0.009 -0.255 -0.171 -0.041 -0.149
    Cash From Financing Activities 9.998 -0.302 -0.109 -0.164 -0.062
    Financing Cash Flow Items -3.123 -0.113
    Issuance (Retirement) of Debt, Net 2.373 -0.289 -0.164 -0.204 -0.062
    Foreign Exchange Effects 0.033 -0.708 -0.998 -0.638 -0.141
    Net Change in Cash 7.813 -11.24 -11.002 -8.654 -6.565
    Issuance (Retirement) of Stock, Net 10.748 0.1 0.055 0.04
    Deferred Taxes 0.116
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Velan Capital Investment Management LP Investment Advisor/Hedge Fund 22.4131 1659654 1401901 2023-05-17 MED
    Ocumension Therapeutics Corporation 15.4621 1144945 0 2023-04-24 LOW
    Morgan Stanley & Co. LLC Research Firm 8.9243 660832 0 2023-03-31 MED
    Caligan Partners, LP Hedge Fund 6.4657 478777 0 2023-05-17 MED
    Eiswirth (Richard S Jr) Individual Investor 4.3555 322518 500 2023-04-24 LOW
    HOOPP Investment Management Pension Fund 3.3762 250000 0 2023-03-31 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0071 148624 0 2023-03-31 LOW
    Ashman Philip Individual Investor 1.8004 133315 0 2023-04-24 MED
    Holland (David R) Individual Investor 1.4704 108880 500 2023-04-24 LOW
    Renaissance Technologies LLC Hedge Fund 1.3693 101394 -1100 2023-03-31 HIGH
    Skibsted (Russell L) Individual Investor 1.0196 75500 58000 2023-03-26 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5167 38262 0 2023-03-31 LOW
    Jones (John Philip) Individual Investor 0.4347 32186 372 2022-10-31
    Millennium Management LLC Hedge Fund 0.3884 28762 16799 2023-03-31 HIGH
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.2639 19542 0 2023-03-31 MED
    Bridgeway Capital Management, LLC Investment Advisor 0.2471 18300 0 2023-03-31
    Perritt Capital Management, Inc. Investment Advisor 0.2431 18000 0 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.175 12962 438 2023-03-31 LOW
    J.P. Morgan Securities LLC Research Firm 0.14 10364 9838 2023-03-31 MED
    Snisarenko (John) Individual Investor 0.135 10000 0 2023-04-24 LOW

    Why choose Capital.com? Our numbers speak for themselves.

    Capital.com Group

    535K+

    Traders

    87K+

    Active clients monthly

    $113M+

    Monthly investing volume

    $64M+

    Withdrawn each month

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Alimera Sciences, Inc. Company profile

    About Alimera Sciences Inc

    Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Alimera Sciences Inc revenues increased 16% to $59M. Net loss decreased 18% to $4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects DEPRECIATION AND AMORTIZATION decrease of 4% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.66.

    Equity composition

    Common Stock $.01 Par, 05/11, 100M auth., 31,348,197 issd. IPO:TBA. Insider owns 2.06%.

    Industry: Biopharmaceuticals

    Ste 290
    6120 Windward Parkway
    ALPHARETTA
    GEORGIA 30005
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Turkish lira on top of USA national currency, top view of mixed American dollars banknotes. TRY and USA paper money. Lira and US dollars exchange rate

    USD/TRY forecast: Turkish lira under pressure from high inflation and low rates

    We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.

    17:07, 1 June 2023
    Nvidia HQ in Santa Clara, California

    Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?

    Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?

    07:46, 31 May 2023
    Alphabet Inc and Google logos on a smartphone screen

    Google stock forecast 2023-2025

    What is the outlook for the tech giant, following a tumultuous 2022?

    18:02, 30 May 2023
    Benjamin Franklin’s face on a $100 bill

    USD forecast: DXY slides in risk-off market sentiment

    The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.

    16:10, 24 May 2023
    Oil wells pictured in an oil field, silhouetted against clouds

    Oil price forecast: Will WTI and Brent regain momentum in 2023?

    Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.

    11:38, 22 May 2023
    businessman using a mobile phone to check stock market data

    Weekly Roundup: Tech stocks lead the way

    US stocks push higher as risk appetite surges despite the uncertainty

    13:39, 19 May 2023
    Japanese yen currency

    USD/JPY continues to build higher towards 138

    USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher

    11:50, 17 May 2023

    People also watch

    US100

    14,553.50 Price
    +0.340% 1D Chg, %
    Long position overnight fee -0.0255%
    Short position overnight fee 0.0032%
    Overnight fee time 21:00 (UTC)
    Spread 3.0

    BTC/USD

    25,697.55 Price
    -2.960% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    Oil - Crude

    70.46 Price
    -0.840% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee -0.0026%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    XRP/USD

    0.49 Price
    -9.180% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.00316

    Still looking for a broker you can trust?

    Join the 535.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading